AR087017A1 - Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos - Google Patents

Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos

Info

Publication number
AR087017A1
AR087017A1 ARP120102378A ARP120102378A AR087017A1 AR 087017 A1 AR087017 A1 AR 087017A1 AR P120102378 A ARP120102378 A AR P120102378A AR P120102378 A ARP120102378 A AR P120102378A AR 087017 A1 AR087017 A1 AR 087017A1
Authority
AR
Argentina
Prior art keywords
hydroxy
represents hydrogen
pyrrolotriazine
indicates
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120102378A
Other languages
English (en)
Inventor
Telser Joachim Dr
Klar Jrgen Dr
Bttger Michael Dr
Schlemmer Karl Dr
Lobell Mario Heinz-Dr
Frank Smeier
Voehringer Verena Dr
Wenlang Fu
Li Volkhart Min Dr
Golz Stefan Jian-Dr
Lang Dieter Dr
Schlange Thomas Dr
Schall Andreas Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47436537&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Publication of AR087017A1 publication Critical patent/AR087017A1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente se refiere a pirrolo[2,1-f][1,2,4]triazin-4-aminas sustituidas con 5-[(hidroximetil)arilo], a procedimientos para la preparación de tales compuestos y a composiciones farmacéuticas que contienen tales compuestos, útiles para tratar trastornos relacionados con la angiogénesis, en particular trastornos oculares relacionados con la angiogénesis.Reivindicación 1: Un compuesto de la fórmula (1) en la que A es N o C-R2, en el que R2 representa hidrógeno, fluoro o cloro; R1 representa hidrógeno, fluoro, cloro, metilo, etilo o metoxi; y Z representa alquilo C1-4 o cicloalquilo C3-6, cada uno de los cuales puede estar sustituido con hidroxi, o Z representa un grupo heterocíclico seleccionado del grupo de fórmulas (2) en la que * indica el punto de unión al resto de pirrolotriazina, y R3 representa hidrógeno o hidroxi, con la condición de que cuando R3 sea hidroxi, este hidroxi no esté unido a un átomo de carbono del anillo situado adyacente al átomo de nitrógeno del anillo, o Z representa un grupo tiazol de la fórmula (3) en la que * indica el punto de unión al resto de pirrolotriazina, y R4 representa hidrógeno, metilo, etilo, amino o aminometilo, o Z representa un grupo seleccionado del grupo de fórmulas (4) en la que * indica el punto de unión al resto de pirrolotriazina, R5 representa cicloalquilo C3-6, oxetanilo, tetrahidrofuranilo o tetrahidropiranilo, R6 representa hidrógeno o hidroxi, R7 representa hidrógeno o hidroxi, con la condición de que cuando R7 sea hidroxi, este hidroxi no esté unido a un átomo de carbono del anillo situado adyacente al átomo de nitrógeno del anillo, e Y es O, NH o NCH3, o una sal, un hidrato y/o un solvato del mismo farmacéuticamente aceptables.
ARP120102378A 2011-07-01 2012-06-29 Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos Pending AR087017A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503840P 2011-07-01 2011-07-01
EP12161547 2012-03-27

Publications (1)

Publication Number Publication Date
AR087017A1 true AR087017A1 (es) 2014-02-05

Family

ID=47436537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102378A Pending AR087017A1 (es) 2011-07-01 2012-06-29 Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos

Country Status (24)

Country Link
US (1) US9040691B2 (es)
EP (1) EP2726482B1 (es)
JP (1) JP5955953B2 (es)
KR (1) KR20140036269A (es)
CN (1) CN103764657B (es)
AP (1) AP3529A (es)
AR (1) AR087017A1 (es)
AU (1) AU2012280508A1 (es)
BR (1) BR112014000049A2 (es)
CA (1) CA2840518A1 (es)
CO (1) CO6870031A2 (es)
CU (1) CU20130170A7 (es)
DO (1) DOP2013000300A (es)
EA (1) EA023775B1 (es)
EC (1) ECSP13013120A (es)
ES (1) ES2598027T3 (es)
GT (1) GT201300313A (es)
IL (1) IL229533A0 (es)
MA (1) MA35601B1 (es)
MX (1) MX2013014315A (es)
PE (1) PE20140570A1 (es)
SG (1) SG195100A1 (es)
UY (1) UY34167A (es)
WO (1) WO2013004551A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2707361T (pt) 2011-05-10 2017-11-28 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de sódio
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
JP6692795B2 (ja) * 2014-04-10 2020-05-13 ランケナー インスティテュート フォー メディカル リサーチ 眼疾患および眼障害の治療のための方法および組成物
DK3148993T3 (da) 2014-05-28 2019-05-20 Bayer Cropscience Ag Fremgangsmåde til fremstilling af thiazolderivater
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
ES2749679T3 (es) * 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
TW201632520A (zh) 2014-11-25 2016-09-16 拜耳製藥股份有限公司 經取代之吡啶並苯並二氮呯酮衍生物及其用途
ES2766835T3 (es) 2015-04-16 2020-06-15 Merck Patent Gmbh Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
SG11201808582RA (en) 2016-03-28 2018-10-30 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
JP2020535168A (ja) 2017-09-27 2020-12-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍ阻害剤として有用なピロロトリアジン誘導体の塩
EP3813800A1 (en) 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010482A (pt) * 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
CA2494179C (en) 2002-08-08 2012-04-24 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
ES2401099T3 (es) 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) * 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
RU2009120389A (ru) * 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
AU2008206406A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
US8143253B2 (en) * 2007-07-26 2012-03-27 Novartis Ag Organic compounds
ES2393430T3 (es) * 2007-10-17 2012-12-21 Novartis Ag Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
CN102056927B (zh) * 2008-05-13 2014-06-25 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds

Also Published As

Publication number Publication date
JP5955953B2 (ja) 2016-07-20
CN103764657B (zh) 2016-05-25
CN103764657A (zh) 2014-04-30
EP2726482B1 (en) 2016-07-20
DOP2013000300A (es) 2014-02-28
CU20130170A7 (es) 2014-04-24
NZ619453A (en) 2016-01-29
MA35601B1 (fr) 2014-11-01
CO6870031A2 (es) 2014-02-20
EP2726482A1 (en) 2014-05-07
SG195100A1 (en) 2013-12-30
US20140256718A1 (en) 2014-09-11
MX2013014315A (es) 2014-01-31
JP2014525902A (ja) 2014-10-02
EA201490103A1 (ru) 2014-06-30
EA023775B1 (ru) 2016-07-29
AP3529A (en) 2016-01-11
CA2840518A1 (en) 2013-01-10
US9040691B2 (en) 2015-05-26
PE20140570A1 (es) 2014-04-28
WO2013004551A1 (en) 2013-01-10
AP2014007378A0 (en) 2014-01-31
GT201300313A (es) 2014-11-13
ECSP13013120A (es) 2014-02-28
CU24146B1 (es) 2016-02-29
UY34167A (es) 2013-01-31
KR20140036269A (ko) 2014-03-25
IL229533A0 (en) 2014-01-30
BR112014000049A2 (pt) 2017-02-07
AU2012280508A1 (en) 2013-12-12
ES2598027T3 (es) 2017-01-24

Similar Documents

Publication Publication Date Title
AR087017A1 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
MX358149B (es) Derivado de pirazoloquinolina.
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR098912A1 (es) Inhibidores de syk
AR100340A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
AR058562A1 (es) Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
CO6251357A2 (es) Nuevos derivados de acido azabifenilaminobenzoico
AR076219A1 (es) Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR058151A1 (es) Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion
AR085327A1 (es) Inhibidores del virus de la hepatitis c
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR085806A1 (es) Inhibidores triciclicos de girasa
PE20160992A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
NI201000011A (es) Derivados de pirimidina 934.
AR091781A1 (es) Antagonistas del receptor de 5-ht3

Legal Events

Date Code Title Description
FB Suspension of granting procedure